Literature DB >> 31692686

Impact of right ventricular dyssynchrony on prognosis of patients with idiopathic pulmonary arterial hypertension.

Xiao-Ling Cheng1, Bing-Yang Liu2, Wei-Chun Wu2, Wen Li2, Li Huang2, Tao Yang2, Zhi-Hong Liu2, Hao Wang2, Jian-Guo He2, Chang-Ming Xiong2.   

Abstract

Idiopathic pulmonary arterial hypertension is a progressive disease with high mortality with an increasing burden of right ventricular. Right ventricular dyssynchrony was observed in idiopathic pulmonary arterial hypertension, but the association with mortality is unclear. This study aimed to investigate the impact of right ventricular dyssynchrony on the survival of idiopathic pulmonary arterial hypertension. A total of 116 patients with idiopathic pulmonary arterial hypertension were enrolled in this study. All these patients underwent comprehensive clinical evaluation. Right ventricular dyssynchrony was assessed by two-dimensional speckle-tracking echocardiography. The time to peak strain (Tpeak) of right ventricular segments were obtained. Right ventricular dyssynchrony was quantified by the standard deviation of the heart rate-corrected Tpeak of right ventricular four segments. All patients were followed up and the primary endpoint was all cause of death. Results found patients with significant right ventricular dyssynchrony present with advanced World Health Organization functional class, worse hemodynamic status and right ventricular function. Right ventricular dyssynchrony was an independent predictive factor for the survival of idiopathic pulmonary arterial hypertension. Kaplan-Meier survival curves showed patients with right ventricular dyssynchrony had worse prognosis. In conclusion, right ventricular dyssynchrony analyzed by speckle-tracking echocardiography provided added value to hemodynamic and echocardiographic parameters in evaluating the survival of patients with idiopathic pulmonary arterial hypertension.
© The Author(s) 2019.

Entities:  

Keywords:  dyssynchrony; prognosis; pulmonary arterial hypertension; right ventricle

Year:  2019        PMID: 31692686      PMCID: PMC6811764          DOI: 10.1177/2045894019883609

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


Introduction

Idiopathic pulmonary arterial hypertension (PAH) is considered as a rare, progressive and life-threatening disease with poor prognosis. Due to luminal obstruction of the distal pulmonary vasculature, pulmonary vascular resistance (PVR) and pulmonary arterial pressure are elevated, and finally leads to right ventricular (RV) failure and death.[1-3] As described in left heart failure, RV adverse remodeling response to the increased afterload may also destroy its mechanical synchronicity. There are differences in the timing of contraction between the different myocardial segments.[4] Recent study observed that the delayed contraction of basal and mid-RV free wall may be the main determinant of intraventricular dyssynchrony in patients with pulmonary hypertension.[5,6] RV dyssynchrony even can be observed in patients with narrow QRS, and is strongly correlates with the extent of RV function impairment. Patients with higher RV dyssynchrony showed a more advanced WHO functional class (WHO-FC) and worse exercise tolerance and would predict clinical worsening in patients with PAH.[7-9] However, the value of RV dyssynchrony to assess the mortality of idiopathic PAH has not been well defined. Therefore, we performed a study with a larger group of patients with idiopathic PAH, and extended the follow-up time to achieve their clinical outcomes to investigate correlations between RV dyssynchrony and the survival of idiopathic PAH.

Methods

Study population

This study included patients who were diagnosed as idiopathic PAH for the first time in our hospital from January 2010 to December 2014, who had underwent comprehensive clinical evaluation. Idiopathic PAH was established according to the guidelines[10] by means of right heart catheterization (RHC). Other specific markers, including WHO-FC, 6-minute walking distance (6MWD) and standard transthoracic echocardiography parameters were sampled at the time of catheterization.[11] Patients with wide QRS (QRS ≥120 ms), which may exert an electromechanical delay, were excluded.

Hemodynamics evaluation

RHC was performed using a standard protocol to measure the hemodynamic parameters, including the cardiac index (CI), pulmonary artery systolic pressure, pulmonary artery diastolic pressure (Pa dias), right ventricular systolic pressure, right ventricular end-diastolic pressure, mean right atrial pressure (MRAP), mixed venous oxygen saturation and pulmonary artery wedge pressure (PAWP). PVR was calculated as MPAP-PAWP, divided by cardiac output.

Standard echocardiographic evaluation

Standard transthoracic echocardiography was obtained with the Philips iE33 system, and images were analyzed offline after the procedure according to the recommendation.[12] RV end-diastolic area (RVEDA) and RV end-systolic area (RVESA) were obtained from the apical four-chamber view. RV fractional area change (RVFAC) was defined as (RVEDA−RVESA)/RVEDA × 100%. Tricuspid annular plane systolic excursion (TAPSE) was acquired by M-mode image, and the cursor was placed through the lateral tricuspid annulus, the displacement of which from the end-diastole to the end-systole was measured. Right ventricular end-systolic volume (RVESV) and right ventricular end-diastolic volume (RVEDV) were detected by three-dimensional echocardiology, and right ventricular ejection fraction (RVEF) was calculated as (RVEDV−RVESV)/RVEDV × 100%. A single experienced sonographer, who was blind of the clinical information of patients, performed image acquisition and analysis.

RV mechanical dyssynchrony analysis

RV mechanical dyssynchrony was analyzed by conventional two-dimensional speckle-tracking echocardiography. RV longitudinal strain was assessed in the apical four-chamber images with a frame rate of 70–80 frames/s. Automated software (CMQ, Q-lab 10.5, Philips) divided the apical four-chamber image into six standard segments (apical, middle and basal of the RV free wall and interventricular septum). Longitudinal strain curves were obtained for six RV segments (shown in Fig. 1) and time to peak-systolic strain (Tpeak, from onset of QRS to the peak-systolic stain) of each segment was measured. As previous report and studies,[7,9] time to peak for RV apical segments were more variable, so that we also use the four-segment RV (RV-SD4) model to calculate the synchronicity index. RV-SD4, the standard deviation (SD) of the heart rate–corrected Tpeak of 4 mid-basal RV segments, was used for qualify RV dyssynchrony.
Fig. 1.

Speckle-tracking strain imaging using the apical four-chamber view to assess RV dyssynchrony. The segmental (colored lines) strain curves represent the relative (percentage) shortening of the six regions of interest as a function of time (in milliseconds). The yellow dots in the segment strain curved represent the peak systolic strain of the segments. (a) A six-segment model of the right ventricle in a control subject; (b) An example of a patient with idiopathic PAH with RV-SD4 = 35 ms.

Speckle-tracking strain imaging using the apical four-chamber view to assess RV dyssynchrony. The segmental (colored lines) strain curves represent the relative (percentage) shortening of the six regions of interest as a function of time (in milliseconds). The yellow dots in the segment strain curved represent the peak systolic strain of the segments. (a) A six-segment model of the right ventricle in a control subject; (b) An example of a patient with idiopathic PAH with RV-SD4 = 35 ms.

Endpoint and follow-up

All patients were followed up by outpatient clinic interview or telephone contact every six months from the date of referring to the hospital. The primary endpoint was all causes of mortality. Survival data were collected in a six-month interval.

Statistical analysis

All the analyses were performed using the Statistical Package for the Social Sciences software (SPSS, version 20.0). Continuous variables were presented as means ± SD. Student’s t-test and analysis of variance (ANOVA) were applied to compare the mean values of continuous variables, and Mann–Whitney U test for ordered variables. A Chi-squared statistics test was used to assess the differences between proportions. Correlations between RV dyssynchrony and hemodynamic variables were explored using Spearman/Pearson’s coefficient analysis. The prognostic value of RV dyssynchrony was tested by univariate and multivariate Cox proportional hazard regression analysis. Kaplan–Meier curves were used to illustrate the timing of endpoints during follow-up. The optimal cut-off value of RV dyssynchrony to predict mortality was determined by receiver operating characteristic (ROC) curve analysis. A p-value of ≤0.05 was considered statistically significant.

Results

Correlations of RV-SD4 with echocardiographic and hemodynamic parameters

Eleven patients were excluded because of poor image quality, and eventually 116 patients with idiopathic PAH were included in this study. The mean age was 32 ± 10 years, and they are mainly female (75.8%). The baseline clinical, echocardiographic and hemodynamic characteristics of the study population are presented in Table 1.
Table 1.

The baseline clinical, echocardiographic and hemodynamic characteristic of the study population.

VariablesValues
Age (years)32 ± 10
Female (n, %)88 (75.9)
WHO-FC
 I, II (n, %)51 (44.0)
 III (n, %)62 (53.4)
 IV (n, %)3 (2.6)
Heart rate (beats/minute)74 ± 12
Systolic blood pressure (mmHg)114 ± 15
Diastolic blood pressure (mmHg)74 ± 12
6MWD (m)422 ± 82
NT-proBNP (fmol/ml)1306.0 ± 821.4
Echocardiographic parameters
 RVFAC (%)29.1 ± 8.3
 TAPSE (mm)16.2 ± 3.5
 LVEF (%)65.0 ± 6.8
 RVEDV (cm[3])125.4 ± 54.8
 RVESV (cm[3])90.4 ± 46.9
 RVEF (%)29.8 ± 9.8
 Tpeak of basal-RVFW (ms)429 ± 70
 Tpeak of mid-RVFW (ms)404 ± 72
 Tpeak of basal-IS (ms)414 ± 75
 Tpeak of mid-IS (ms)396 ± 68
 RV-SD4 (ms)31 ± 23
Hemodynamic parameters
 MRAP (mmHg)6 ± 5
 MPAP (mmHg)59 ± 18
 PVR (wood units)14.9 ± 7.5
 CI (l/min/m2)2.7 ± 0.9
Target therapy
 Sildenafil (n, %)70 (60.3)
 Bosentan (n, %)14 (12.1)
 Ambrisentan (n, %)6 (5.2)
 Inhaled iloprost (n, %)7 (6.1)
 Calcium channel blockers (n, %)15 (12.9)
 None (n, %)4 (3.4)

Note: Data are presented as n (%) and mean ± SD. WHO-FC: World Health Organization functional class; 6MWD: 6-minute walking distance; LVEF: left ventricular ejection fraction; RVFAC: right ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; Tpeak: time to peak-systolic strain; RVFW: right ventricular free wall; IS: interventricular septum; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index.

The baseline clinical, echocardiographic and hemodynamic characteristic of the study population. Note: Data are presented as n (%) and mean ± SD. WHO-FC: World Health Organization functional class; 6MWD: 6-minute walking distance; LVEF: left ventricular ejection fraction; RVFAC: right ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; Tpeak: time to peak-systolic strain; RVFW: right ventricular free wall; IS: interventricular septum; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index. Correlations between RV-SD4 with echocardiographic and hemodynamic parameters are detailed in Table 2. RV-SD4 had positive correlations with RVESV (r = 0.562, p < 0.001), RVEDV (r = 0.538, p < 0.001), PVR (r = 0.368, p < 0.001), and negative correlations with TAPSE (r = −0.375, p < 0.001), RVFAC (r = −0.411, p < 0.001), RVEF (r = −0.349, p < 0.001) and CI (r = −0.445, p < 0.001).
Table 2.

Correlations between RV-SD4 and echocardiographic, hemodynamic parameters.

VariablesRV-SD4
Rp-Value
Echocardiographic parameters
 TAPSE−0.375<0.001
 RVESV0.562<0.001
 RVEDV0.538<0.001
 RVEF−0.349<0.001
 LVEF−0.2300.018
 RVFAC−0.411<0.001
Hemodynamic parameters
 MRAP0.2020.032
 RVSP0.1540.099
 RVEDP0.2130.022
 MPAP0.1710.067
 CI−0.445<0.001
 PVR0.368<0.001

TAPSE: tricuspid annular plane systolic excursion; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; LVEF: left ventricular ejection fraction; RVFAC: right ventricular fractional area change; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index; RVSP: right ventricular systolic pressure; RVEDP: right ventricular end-diastolic pressure.

Correlations between RV-SD4 and echocardiographic, hemodynamic parameters. TAPSE: tricuspid annular plane systolic excursion; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; LVEF: left ventricular ejection fraction; RVFAC: right ventricular fractional area change; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index; RVSP: right ventricular systolic pressure; RVEDP: right ventricular end-diastolic pressure.

Clinical characteristics based on RV dyssynchrony

All the patients were divided into three tertiles based on the RV-SD4. Characteristics of the patients in the three groups are shown in Table 3. There was a significant gradient in severity of most variables among the three groups. Patients in the upper tertiles of RV dyssynchrony distribution experienced a more impaired WHO-FC, worse hemodynamic status and RV function. RV remodeling in the upper tertiles was also more significant, as RVEDV (165.2 ± 63.1 vs. 108.6 ± 40.8, 105.2 ± 37.0 cm3, p < 0.001) and RVESV (124.9 ± 55.7 vs. 78.6 ± 32.5, 70.2 ± 30.3 cm3, p < 0.001) were larger than the other groups. The plasma level of NT-proBNP of the intermediate and upper tertiles was higher than the lower tertile groups (1245.0 ± 734.6, 1628.4 ± 939.6 vs.1059.8 ± 691.1 fmol/ml, p = 0.008), which means worse RV function in these patients.
Table 3.

Comparison between patients with idiopathic PAH based on RV dyssynchrony.

VariablesLower tertiles (n = 39)Intermediate tertiles (n = 39)Upper tertiles (n = 38)p-Value
Age (years)34 ± 1031 ± 1031 ± 110.402
WHO-FC0.031
 I, II (n, %)23 (59.0)15 (38.5)13 (34.2)
 III, IV (n,%)16 (41.0)24 (61.5)25 (65.8)
6MWD (m)439 ± 77415 ± 82411 ± 870.306
NT-proBNP (fmol/ml)1059.8 ± 691.11245.0 ± 734.61628.4 ± 939.60.008
Echocardiographic parameters
 RVEDV (cm[3])105.2 ± 37.0108.6 ± 40.8165.2 ± 63.1<0.001
 RVESV (cm[3])70.2 ± 30.378.6 ± 32.5124.9 ± 55.7<0.001
 RVEF (%)34.6 ± 9.428.0 ± 8.526.3 ± 9.6<0.001
 RVFAC (%)33.2 ± 9.829.1 ± 7.525.0 ± 4.9<0.001
 TAPSE (mm)17 ± 316 ± 315 ± 30.002
 LVEF (%)66.6 ± 6.363.9 ± 6.264.4 ± 7.70.202
Hemodynamic parameters
 MRAP (mmHg)5 ± 46 ± 57 ± 50.191
 CI (l/min.m2)3.2 ± 1.02.7 ± 0.62.2 ± 0.6<0.001
 MPAP (mmHg)56 ± 1858 ± 1764 ± 170.131
 PVR (wood units)11.9 ± 6.114.1 ± 7.418.6 ± 7.5<0.001

Note: Data are presented as n (%) and mean ± SD. WHO-FC: World Health Organization functional class; 6MWD: 6-minute walking distance; TAPSE: tricuspid annular plane systolic excursion; LVEF: left ventricular ejection fraction; RVFAC: right ventricular fractional area change; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index.

Comparison between patients with idiopathic PAH based on RV dyssynchrony. Note: Data are presented as n (%) and mean ± SD. WHO-FC: World Health Organization functional class; 6MWD: 6-minute walking distance; TAPSE: tricuspid annular plane systolic excursion; LVEF: left ventricular ejection fraction; RVFAC: right ventricular fractional area change; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index.

Univariate and multivariate Cox proportional hazard analysis for parameters to predict mortality

The mean duration of follow-up was 41 ± 15 months. During this period, eight patients (7%) were lost, and 93% patients were followed up for at least three years or until death. There were 19 deaths (all causes) and most were died of right heart failure. The baseline clinical and hemodynamic characteristics of the deceased patients are described in Table 4. Among these patients, 18 were WHO-FC III at enrollment. Seventeen patients received PAH-specific drugs combined with conventional therapy as soon as the PAH diagnoses were confirmed. However, the other two patients only received conventional supportive therapy including diuretics, oxygen and digoxin because of financial issues. Compared with survivors, deceased patients had decreased 6MWD (386 ± 78 vs. 429 ± 82 m, p = 0.045), higher NT-proBNP (1728.0 ± 1148.6 vs. 1221.7 ± 717.8 fmol/ml, p = 0.014) and worse hemodynamics.
Table 4.

Baseline demographics, and clinical and hemodynamic characteristic of the survival and deceased patients.

VariablesSurvivors (n = 97)Non-survivors (n = 19)p-Value
Age (years)32 ± 1031 ± 130.806
Female (n, %)78 (80.4)10 (52.6)<0.001
WHO-FC<0.001
 I/II (n, %)47 (48.5)4 (21.1)
 III/ IV (n, %)50 (51.5)15 (78.9)
Heart rate (beats/minute)74 ± 1279 ± 110.035
Systolic blood pressure (mmHg)114 ± 14111 ± 190.469
Diastolic blood pressure (mmHg)74 ± 1275 ± 130.655
6MWD (m)429 ± 82386 ± 780.045
NT-proBNP (fmol/ml)1221.7 ± 717.81728.0 ± 1148.60.014
Echocardiographic parameters
 TAPSE (mm)16.5 ± 3.514.6 ± 2.80.031
 RVEDV (cm[3])115.0 ± 47.5175.2 ± 61.1<0.001
 RVESV (cm[3])81.8 ± 41.8131.4 ± 49.3<0.001
 RVEF (%)30.7 ± 10.125.3 ± 6.10.027
 LVEF (%)65.4 ± 6.962.9 ± 5.90.182
 RV-SD4 (ms)25.9 ± 20.554.2 ± 22.9<0.001
Hemodynamic parameters
 MRAP (mmHg)5.0 ± 4.59.2 ± 4.2<0.001
 MPAP (mmHg)57.9 ± 17.466.3 ± 17.30.058
 PVR (wood units)13.8 ± 6.820.2 ± 9.10.001
 CI (l/min/m2)2.8 ± 0.92.2 ± 0.60.002
Target therapy (yes)95 (97.9)17 (89.4)0.064
 Sildenafil (n, %)62 (63.9)8 (42.1)
 Bosentan (n, %)9 (9.3)5 (26.3)
 Ambrisentan (n, %)6 (6.2)0 (0)
 Inhaled iloprost (n, %)3 (3.1)4 (21.1)
 Calcium channel blockers (n, %)15 (15.4)0 (0)
 None (n, %)2 (2.1)2 (10.5)

Note: Data are presented as n (%) and mean ± SD. WHO-FC: World Health Organization functional class; 6MWD: 6-minute walking distance; LVEF: left ventricular ejection fraction; RVFAC: right ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index.

Baseline demographics, and clinical and hemodynamic characteristic of the survival and deceased patients. Note: Data are presented as n (%) and mean ± SD. WHO-FC: World Health Organization functional class; 6MWD: 6-minute walking distance; LVEF: left ventricular ejection fraction; RVFAC: right ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume; RVEF: right ventricular ejection fraction; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index. Univariate Cox regression analysis determined that TAPSE, RVFAC, RVEDV, RVEF, MRAP, CI, PVR and RV-SD4 were predictive factors for death. In multivariate Cox proportional hazard analysis, the results showed that RV-SD4 still had the ability to independently predict the mortality after adjusted by other factors (HR = 1.425, p < 0.001) (Table 5).
Table 5.

The results of univariate and multivariate Cox regression analysis for 116 patients with idiopathic PAH.

VariablesUnivariate Cox regression
Multivariate Cox regression
Hazard ratio (95% CI)p-ValueHazard ratio (95% CI)p-Value
Echocardiographic parameters
 TAPSE (mm)0.852 (0.740–0.982)0.0261.066 (0.857–1.328)0.565
 RVFAC (%)0.932 (0.872–0.996)0.0370.994 (0.905–1.091)0.893
 RVEDV (cm[3])1.013 (1.006–1.021)0.0011.005 (0.994–1.016)0.375
 RVEF (%)0.946 (0.897–0.998)0.0431.025 (0.954–1.102)0.497
 RV-SD4 (ms)1.473 (1.237–1.755)<0.0011.425 (1.185–1.714)<0.001
Hemodynamic parameters
 MRAP (mmHg)1.115 (1.033–1.203)0.0051.166 (1.058–1.286)0.002
 MPAP (mmHg)1.017 (0.996–1.039)0.111
 CI (l/min.m2)0.208 (0.077–0.567)0.0021.068 (0.326–3.502)0.913
 PVR (wood units)1.075 (1.031–1.122)0.0011.005 (0.994–1.016)0.078

WHO-FC: World Health Organization functional class; 6MWD: 6-minute walking distance; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index. RVFAC: right ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; RVESV: right ventricular end-systolic volume.

The results of univariate and multivariate Cox regression analysis for 116 patients with idiopathic PAH. WHO-FC: World Health Organization functional class; 6MWD: 6-minute walking distance; MRAP: mean right atrial pressure; MPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; CI: cardiac index. RVFAC: right ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; RVESV: right ventricular end-systolic volume. ROC curve analysis was performed to evaluate the utility of RV-SD4 as predictor for mortality. According to the ROC curve analysis, the cut-off value of RV-SD4 was 37.6 ms (AUC = 0.812, p < 0.001), with a sensitivity of 84.2% and a specificity of 80.4%. The Kaplan–Meier survival analysis showed that patients with RV-SD4 > 37.6 ms had worse prognosis (Log-rank, p < 0.001; Fig. 2).
Fig. 2.

Kaplan–Meier survival curve for the idiopathic PAH patients with RV-SD4 > 37.6 ms or RV-SD4 < 37.6 ms.

Kaplan–Meier survival curve for the idiopathic PAH patients with RV-SD4 > 37.6 ms or RV-SD4 < 37.6 ms.

Reproducibility of RV-SD4

RV-SD4 was repeatedly measured in 20 randomly selected patients, and the interobserver and intraobserver variabilities are shown in Fig. 3, which was assessed by the Bland–Altman method. As a result, the reasonable reproducibility of intraventricular dyssynchrony evaluated by speckle-tracking echocardiography in this study was demonstrated.
Fig. 3.

Interobserver (a) and intraobserver (b) reproducibility Bland–Altman plots for the right ventricular dyssynchrony (RV-SD4).

Interobserver (a) and intraobserver (b) reproducibility Bland–Altman plots for the right ventricular dyssynchrony (RV-SD4).

Discussion

Idiopathic PAH is characterized by pulmonary vascular remodeling, which leads to elevated pulmonary artery pressure and RV failure. RV remodeling responses to chronic pulmonary hypertension is a major cause of RV failure,[1,2,13-15] which often includes the adaptive stage and maladaptive stage. The former is associated with more concentric remodeling and preserved systolic function, whereas the latter is characterized by more eccentric hypertrophy and worse systolic function.[16,17] Extensive investigations concerning left ventricular dyssynchrony suggest that exploration synchronicity of the RV may be a productive approach to understand RV dysfunction in PAH. Previous studies[18-20] suggest that RV dyssynchrony is a marker of maladaptive remodeling and more severe dysfunction. In our study, we also found patients with greater RV dilatation had more significant RV dyssynchrony and poor pump function. In contrast to the well-studied pathophysiology of LV dyssynchrony, the underlying mechanisms of dyssynchrony in the right ventricle remain largely unexplored. Recently, Gabrielli et al.[21] showed that in patients with PAH iloprost inhalation induced an acute reduction in RV peak systolic strain dyssynchrony index together with a better RV performance. Iloprost inhalation has been widely used in patients with PAH and is proved to be able to improve their hemodynamics. In this study, patients with QRS ≥120 ms were excluded, so an acute RV afterload reduction with inhaled iloprost may explain these changes in RV synchronicity. In concordance with recent study, we also showed patients with higher pulmonary arterial pressure and resistance demonstrated significant RV dyssynchrony. The differential effect of elevated pressure overload on RV regional contractility might be attributed to the uneven distribution of mechanical properties across each RV segment caused by the complex structure and the distortion imposed by RV remodeling. Outcome prediction in patients with idiopathic PAH has been extensively studied. One consistent finding among studies is that survival in idiopathic PAH is closely related to the status of RV rather than the increased pressure overload.[22,23] Studies about hemodynamics had demonstrated the predictive value of MRAP and CI;[24-26] magnetic resonance imaging studies had proved the value of stroke volume and RVEF.[23,27,28] Echocardiographic studies found TAPSE and RVFAC had the predictive value in PAH.[29,30] Because hemodynamics assessed by RHC is invasive and magnetic resonance imaging is more expensive, echocardiography is the most common and convenient method used to evaluate RV function. RV dyssynchrony had been described by speckle-tracking echocardiography. Researches by Murata et al.[31] and Badagliacca et al.[9] had also discovered the prognosis value of RV dyssynchrony. However, the prior study included a heterogeneous population of PH patients in terms of etiology, which are different in the natural progress and prognosis and may affect the results. In addition, in the two studies, the endpoint was complicated. For example, hospitalization and worsening in exercise capacity were regarded as primary outcome. As we know, we reported for the first time the association between RV dyssynchrony and the mortality of idiopathic PAH. Our study emphasized that the RV dyssynchrony is a predictor of survival in patients with idiopathic PAH, and after adjusting by MRAP, CI, TAPSE and RVFAC, RV dyssynchrony could independently predict survival. This study had several limitations. Firstly, the main limitation is the two-dimensional approach. We assessed RV synchronicity only in the apical four-chamber view, and RV free wall is not seen in its full extent. However, the apical four-chamber view mainly encompasses the lateral portion of the free wall and interventricular septum, which account for a significant part of RV function through its longitudinal shortening according to the earlier study.[32,33] Therefore, although far from conclusive, this approach might provide a relatively accurate model to evaluate RV synchronicity. Secondly, this was an observational study and was not able to provide information about the possible pathophysiologic mechanisms that underlie dyssynchrony in the right ventricle. Different from left heart failure, dilated right ventricle could also present with dyssynchrony in the absence of right bundle branch block. As in previous researches, RV dyssynchrony partners with adverse RV remodeling and dysfunction were seen in idiopathic PAH, but it is not clear whether RV dyssynchrony is the cause of RV dysfunction or just one of its marker. The mechanisms of RV dyssynchrony and its clinical use wait testing in the forge of additional research. At last, this study involved patients from a particular center. Therefore, we cannot exclude the possibility of biased estimates for the prevalence and degree of RV dyssynchrony in idiopathic PAH. Future studies with larger patient populations from multiple centers are necessary to verify the results. In conclusion, RV dyssynchrony analyzed by speckle-tracking echocardiography provided added value to RHC and standard echocardiography in evaluating the survival of patients with idiopathic PAH.
  33 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

Review 2.  Anatomy and physiology of the right ventricle.

Authors:  Louis J Dell'Italia
Journal:  Cardiol Clin       Date:  2012-05       Impact factor: 2.213

Review 3.  Pulmonary arterial hypertension.

Authors:  Harrison W Farber; Joseph Loscalzo
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

Review 4.  Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.

Authors:  Anton Vonk-Noordegraaf; François Haddad; Kelly M Chin; Paul R Forfia; Steven M Kawut; Joost Lumens; Robert Naeije; John Newman; Ronald J Oudiz; Steve Provencher; Adam Torbicki; Norbert F Voelkel; Paul M Hassoun
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

5.  Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

Authors:  Raymond L Benza; Dave P Miller; Mardi Gomberg-Maitland; Robert P Frantz; Aimee J Foreman; Christopher S Coffey; Adaani Frost; Robyn J Barst; David B Badesch; C Gregory Elliott; Theodore G Liou; Michael D McGoon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

6.  Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension.

Authors:  Stefano Ghio; Catherine Klersy; Giulia Magrini; Andrea Maria D'Armini; Laura Scelsi; Claudia Raineri; Michele Pasotti; Alessandra Serio; Carlo Campana; Mario Viganò
Journal:  Int J Cardiol       Date:  2008-12-12       Impact factor: 4.164

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

8.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

Review 9.  Relevant issues in the pathology and pathobiology of pulmonary hypertension.

Authors:  Rubin M Tuder; Stephen L Archer; Peter Dorfmüller; Serpil C Erzurum; Christophe Guignabert; Evangelos Michelakis; Marlene Rabinovitch; Ralph Schermuly; Kurt R Stenmark; Nicholas W Morrell
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

10.  Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class.

Authors:  Angel López-Candales; Kaoru Dohi; Navin Rajagopalan; Matthew Suffoletto; Srinivas Murali; John Gorcsan; Kathy Edelman
Journal:  Cardiovasc Ultrasound       Date:  2005-08-29       Impact factor: 2.062

View more
  1 in total

1.  Two-dimensional speckle tracking echocardiography detected interventricular dyssynchrony predicts exercise capacity and disease severity in pre-capillary pulmonary hypertension.

Authors:  Bing-Yang Liu; Wei-Chun Wu; Qi-Xian Zeng; Zhi-Hong Liu; Li-Li Niu; Yue Tian; Xiao-Ling Cheng; Qin Luo; Zhi-Hui Zhao; Li Huang; Hao Wang; Jian-Guo He; Chang-Ming Xiong
Journal:  Ann Transl Med       Date:  2020-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.